Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

67 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC).
Johnson B, Haymaker CL, Parra ER, Soto LMS, Wang X, Thomas JV, Dasari A, Morris VK, Raghav K, Vilar E, Kee BK, Eng C, Parseghian CM, Wolff RA, Lee Y, Lorenzini D, Laberiano-Fernandez C, Verma A, Lang W, Wistuba II, Futreal A, Kopetz S, Overman MJ. Johnson B, et al. Among authors: lorenzini d. J Immunother Cancer. 2022 Aug;10(8):e005332. doi: 10.1136/jitc-2022-005332. J Immunother Cancer. 2022. PMID: 36007963 Free PMC article. Clinical Trial.
Monocytes in leukapheresis products affect the outcome of CD19-targeted CAR T-cell therapy in patients with lymphoma.
Carniti C, Caldarelli NM, Agnelli L, Torelli T, Ljevar S, Jonnalagadda S, Zanirato G, Fardella E, Stella F, Lorenzini D, Brich S, Arienti F, Dodero A, Chiappella A, Magni M, Corradini P. Carniti C, et al. Among authors: lorenzini d. Blood Adv. 2024 Apr 23;8(8):1968-1980. doi: 10.1182/bloodadvances.2024012563. Blood Adv. 2024. PMID: 38359407 Free PMC article.
Pilot Clinical Trial of Perioperative Durvalumab and Tremelimumab in the Treatment of Resectable Colorectal Cancer Liver Metastases.
Kanikarla Marie P, Haymaker C, Parra ER, Kim YU, Lazcano R, Gite S, Lorenzini D, Wistuba II, Tidwell RSS, Song X, Foo WC, Maru DM, Chun YS, Futreal A, Kee B, Menter D, Solis L, Tzeng CW, Parseghian C, Raghav K, Morris V, Chang CC, Jenq R, Tam A, Bernatchez C, Kopetz S, Vauthey JN, Overman MJ. Kanikarla Marie P, et al. Among authors: lorenzini d. Clin Cancer Res. 2021 Jun 1;27(11):3039-3049. doi: 10.1158/1078-0432.CCR-21-0163. Epub 2021 Apr 2. Clin Cancer Res. 2021. PMID: 33811152 Free PMC article. Clinical Trial.
Genotype-to-Phenotype Associations in the Aggressive Variant Prostate Cancer Molecular Profile (AVPC-m) Components.
Soundararajan R, Viscuse P, Pilie P, Liu J, Logotheti S, Laberiano Fernández C, Lorenzini D, Hoang A, Lu W, Soto LMS, Wistuba II, Xu M, Song X, Shepherd PDA, Navone NM, Tidwell RSS, Lozano G, Logothetis C, Zhang J, Long JP, Estecio MR, Tzelepi V, Aparicio AM. Soundararajan R, et al. Among authors: lorenzini d. Cancers (Basel). 2022 Jun 30;14(13):3233. doi: 10.3390/cancers14133233. Cancers (Basel). 2022. PMID: 35805010 Free PMC article.
Targeting de novo lipogenesis and the Lands cycle induces ferroptosis in KRAS-mutant lung cancer.
Bartolacci C, Andreani C, Vale G, Berto S, Melegari M, Crouch AC, Baluya DL, Kemble G, Hodges K, Starrett J, Politi K, Starnes SL, Lorenzini D, Raso MG, Solis Soto LM, Behrens C, Kadara H, Gao B, Wistuba II, Minna JD, McDonald JG, Scaglioni PP. Bartolacci C, et al. Among authors: lorenzini d. Nat Commun. 2022 Jul 26;13(1):4327. doi: 10.1038/s41467-022-31963-4. Nat Commun. 2022. PMID: 35882862 Free PMC article.
Author Correction: Targeting de novo lipogenesis and the Lands cycle induces ferroptosis in KRAS-mutant lung cancer.
Bartolacci C, Andreani C, Vale G, Berto S, Melegari M, Crouch AC, Baluya DL, Kemble G, Hodges K, Starrett J, Politi K, Starnes SL, Lorenzini D, Raso MG, Solis Soto LM, Behrens C, Kadara H, Gao B, Wistuba II, Minna JD, McDonald JG, Scaglioni PP. Bartolacci C, et al. Among authors: lorenzini d. Nat Commun. 2022 Aug 8;13(1):4640. doi: 10.1038/s41467-022-32459-x. Nat Commun. 2022. PMID: 35941179 Free PMC article. No abstract available.
The identification of TCF1+ progenitor exhausted T cells in THRLBCL may predict a better response to PD-1/PD-L1 blockade.
Tabanelli V, Melle F, Motta G, Mazzara S, Fabbri M, Agostinelli C, Calleri A, Del Corvo M, Fiori S, Lorenzini D, Cesano A, Chiappella A, Vitolo U, Derenzini E, Griffin GK, Rodig SJ, Vanazzi A, Sabattini E, Tarella C, Sapienza MR, Pileri SA. Tabanelli V, et al. Among authors: lorenzini d. Blood Adv. 2022 Aug 9;6(15):4634-4644. doi: 10.1182/bloodadvances.2022007046. Blood Adv. 2022. PMID: 35767735 Free PMC article.
PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 <50%: a multiomics analysis.
Lo Russo G, Prelaj A, Dolezal J, Beninato T, Agnelli L, Triulzi T, Fabbri A, Lorenzini D, Ferrara R, Brambilla M, Occhipinti M, Mazzeo L, Provenzano L, Spagnoletti A, Viscardi G, Sgambelluri F, Brich S, Miskovic V, Pedrocchi ALG, Trovo' F, Manglaviti S, Giani C, Ambrosini P, Leporati R, Franza A, McCulloch J, Torelli T, Anichini A, Mortarini R, Trinchieri G, Pruneri G, Torri V, De Braud F, Proto C, Ganzinelli M, Garassino MC. Lo Russo G, et al. Among authors: lorenzini d. J Immunother Cancer. 2023 Jun;11(6):e006833. doi: 10.1136/jitc-2023-006833. J Immunother Cancer. 2023. PMID: 37286305 Free PMC article. Clinical Trial.
Primary cutaneous gamma delta T-cell lymphoma: a unique polymorphic cutaneous presentation with hemophagocytic lymphohistiocytosis, and bone marrow Acremonium kiliense infection.
Cammarata E, Esposto E, Andreassi M, Fiori S, Lorenzini D, Gironi LC, Veronese F, Savoia P. Cammarata E, et al. Among authors: lorenzini d. Ital J Dermatol Venerol. 2022 Oct;157(5):466-467. doi: 10.23736/S2784-8671.22.07315-7. Ital J Dermatol Venerol. 2022. PMID: 36213981 No abstract available.
67 results